1Caston JJ,Linares M J,Gallego C,et al.Risk factors for pulmo-nary Aspergillus terreus infection in patients with positive culture for filamentous fungi[ J ].Chest,2007,131(1):230-236. 被引量：1
2Samarakoon P,Soabani A.Invasive pulmonary aspergillosis in patients with COPD:a report of five cases and systematic review of the literature [ J ].Chron Respir Dis,2008,5(1):19-27. 被引量：1
3Tutar N,Metan G,Koc AN,et al.Invasive pulmonary aspergil-losis in patients with chronic obstructive pulmonary disease [ J ].Multidiscip Respir Med,2013,8(1):59. 被引量：1
5Walsh TJ,Anaissie E J,Denning DW,et al.Treatment of asper-gillosis:clinical practice guidelines of the Infectious Diseases So-ciety of America[J].Clin Infect Dis,2008,46(3):327-360. 被引量：1
8Bateman E,Hurd S,Barnes P,et al.Global strategy for asthma management and prevention:GINA executive summary [ J ].Eur Respir J,2008,31(1):143-178. 被引量：1
9Cho JY.Recent advances in mechanisms and treatments of airway remodeling in asthma:a message from the bench side to the clinic [J].Korean J Intern Med,2011,26(4):367-383. 被引量：1
10Vignola AM,Mirabella F,Costanzo G,et al.Airway remodeling in asthma[J].Chest,2003,123(3 Suppl):S417-S422. 被引量：1
3Becker M J, Lugtenburg E J, Cornelissen J J, et al. Galactomannan detection in computerized tomography-based broncho-alveolar lavage fluid and serum in haematological patients at risk for invasive pulmonary aspergillosis. Br J Haematol, 2003; 121:448 ～ 457 被引量：1
4Wingard JR, White MH, Anaissie E, et al. A randomized, double-blind comparative trial evaluating the safety of liposomal amphoteric in B versus amphotericin B lipid complex in the empirical treatment of febrile neutropenia. Clin Infect Dis, 2000;31:1155～ 1163 被引量：1
5Takemoto K, Yamamoto Y, Ueda Y, et al. Comparative studies on the efficacy of AmBisome and fungizone in a mouse model of disseminated aspergillosis. J Antimicrob Chemother,2004;53:311 ～ 317 被引量：1
6Caillot D. Intravenous itraconazole followed by oral itraconazole for the treatment of amphotericin-B-refractory invasive pulmonary aspergillosis. Acta Haematol, 2003; 109: 111 ～ 118 被引量：1
7Herbrecht R, Denning DW, Patterson TF, et al. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med ,2002;347:408 ～ 415 被引量：1
8Yuet W. Voriconazole versue amphotericin for primary therapy of invasive aspergillosis. N Engl J Med, 2002; 347: 408 ～ 415 被引量：1
9Petraitiene R, Petraitis V, Groll AH, et al. Antifungal activity and pharmacokinetics of posaconazole (SCH 56592) in treatment and prevention of experimental invasive pulmonary aspergillosis: correlation with galactomannan antigenemia. Antimicrob Agents Chemother, 2001 ;45: 857 ～ 869 被引量：1
10Taccone FS, Marechal R, Meuleman N, et al. Caspofungin salvage therapy in a neutropenic patient with probable invasive aspergillosis: a case report. Support Care Cancer, 2003; 11: 742 ～744 被引量：1
5Lin S J, Schranz J, Teutsch SM, et al. Aspergillosis case-fatality rate: systematic review of the literature [ J ]. Clin Infect Dis, 2001, 32(3) : 358-366. 被引量：1
6Netea MG, Van der Graaf C, Van der Meer JW, et al. Recogni- tion of fungal pathogens by Toll-like receptors[ J]. Eur J Clin Mi- crobiol Infect Dis, 2004, 23(9): 672-676. 被引量：1
7Meier A, Kirschning CJ, Nikolaus T, et al. Toll-like receptor (TLR) 2 and TLR4 are essential for Aspergillus-induced activa- tion of murine macrophages [ J ]. Cell Microbiol, 2003, 5 ( 8 ) : 561-570. 被引量：1
8Braedel S, Radsak M, Einsele H, et al. Aspergillus fumigatus an- tigens activate innate immune cells via toll-like receptors 2 and 4[J]. Br J Haematol, 2004, 125(3) : 392-399. 被引量：1
9Bellocchio S, Montagnoli C, Bozza S, et al. The contribution of the Toll-like/IL-1 receptor superfamily to innate and adaptive im- munity to fungal pathogens in vivo [ J ]. J Immunol Res, 2004, 172(5) : 3059-3069. 被引量：1
10Romani L. Immunity to fungal infections[ J]. Nat Rev Immunol, 2011, 11(4) : 275-288. 被引量：1
